Determine Immunoglobulin G4 (IgG4) Standards for Cow's Milk and Egg in Different Populations of Allergic and Non-allergic Children

Sponsor
Assistance Publique - Hôpitaux de Paris (Other)
Overall Status
Recruiting
CT.gov ID
NCT03776474
Collaborator
(none)
500
1
36
13.9

Study Details

Study Description

Brief Summary

The study objectives are :

Determine standards of plasma levels of casein-specific immunoglobulin G4 (IgG4) and egg-specific immunoglobulin G4 (IgG4) as a function of age, in non-allergic children, in allergic children, and in cured former allergic patients.

Analyze the plasma IgG4 / IgE ratio, according to the result of the oral provocation test (tolerance versus allergy) and, in the event of a reaction, according to the reactogenic dose (dose which caused the reaction).Determine whether analysis of the plasma metabolome can identify children with a cured allergy to cow's milk protein or to egg from those with a persistent allergy.

Condition or Disease Intervention/Treatment Phase
  • Biological: Blood collection

Detailed Description

Immunoglobulin E (IgE) mediated allergies to cow's milk and hen's egg affects 2-3% and 0.5-2.5% of children respectively. These allergies expose to the risk of immediate anaphylactic reaction that may be life-threatening. Approximately 70-80% of children with IgE mediated allergies to cow's milk and hen's egg will tolerate these foods by the age of 6 years. However, in the absence of reliable biomarker of tolerance, to determine whether oral tolerance is obtained, it is recommended to perform an oral food challenge (OFC) in a hospital setting. This procedure is expensive, time consuming, and carries the risk of anaphylactic reactions. Many studies have tried to find predictive markers of reactivity during the OFC. Improving the prediction of the response to OFC would be very useful to better select children in whom an OFC can be performed without risk to confirm the acquisition of tolerance.

For instance, serum specific IgE positive values beyond which 95% of patients would have an allergic reaction have been proposed. These values are highly variable from one study to another because of methodological differences and heterogeneity of populations, and cannot be used in clinical practice.

The regular dosage of serum specific IgE and its evolution over time is used in clinical practice to predict a possible persistence of IgE mediated food allergy. Indeed, an initial high rate and/or elevation of specific IgE levels may be predictive of a persistent allergy, while initial low rates and a decrease in specific IgE may predict tolerance. When tolerance develops, there is a decrease in specific IgE levels, however, even if tolerance is obtained, they can remain positive at pathological levels.

During continuous exposure to an allergen, the specific immunoglobulin G4 (IgG4) response is physiological. Oral immunotherapy studies in food allergies showed an elevation of specific IgG4, associated with an elevation in the number of regulatory T lymphocytes (LTreg) and the production of interleukin (IL)-10. The development of spontaneous oral tolerance, without the intervention of immunotherapy, also seems to involve IgG4. In a prospective follow-up of a cohort of children with an IgE-mediated cow's milk allergy, the elevation of specific IgG4 was observed in those who cure of their allergy, with rates higher than those observed in children whose allergy persists. In children with cow's milk and/or egg allergies, a low concentration of specific (IgG4 of B-Lactoglobulin or ovalbumin is associated with the need for a more prolonged exclusion diet. The balance between specific IgE and IgG4 therefore appears to be important in the development of tolerance and may reflect the balance between effector T cells and LTreg. However, the normal serum levels of IgG4 to cow's milk and hen's egg are unknown.

A recently published study of Doctor Guillaume Lezmi and Professor Karine Adel-Patient shows that children with an IgE-mediated allergy to cow's milk protein and those who outgrew this allergy, have distinct plasma metabolomic signature. This suggests that plasma metabolomic analysis may be a useful too to differentiate children with a persistent cow's milk protein allergy from those who acquired tolerance to cow's milk. If confirmed, the metabolic signature may be useful to better identify children to whom an oral food challenge with cow's milk protein could be propose. These results need to be confirmed in a larger population and in other food allergies.

The study objectives are :

Determine standards of plasma levels of casein-specific immunoglobulin G4 (IgG4) and egg-specific immunoglobulin G4 (IgG4) as a function of age, in non-allergic children, in allergic children, and in cured former allergic patients.

Analyze the plasma IgG4 / IgE ratio, according to the result of the oral provocation test (tolerance versus allergy) and, in the event of a reaction, according to the reactogenic dose (dose which caused the reaction).

Determine whether analysis of the plasma metabolome can identify children with a cured allergy to cow's milk protein or to egg from those with a persistent allergy.

Study Design

Study Type:
Observational
Anticipated Enrollment :
500 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
Determine Immunoglobulin G4 (IgG4) Standards for Cow's Milk and Egg in Different Populations of Allergic and Non-allergic Children
Actual Study Start Date :
Nov 18, 2020
Anticipated Primary Completion Date :
Nov 18, 2023
Anticipated Study Completion Date :
Nov 18, 2023

Arms and Interventions

Arm Intervention/Treatment
Allergic

Minors allergic to cow's milk and/or eggs

Biological: Blood collection
Patients less than 5 kg : 2 ml Patients over 5 kg : 3 ml Patients over 10 kg : 5 ml

Non-allergic

Minors without history of allergy to cow's milk and/or eggs

Biological: Blood collection
Patients less than 5 kg : 2 ml Patients over 5 kg : 3 ml Patients over 10 kg : 5 ml

Acquired tolerance

Minors formerly allergic to cow's milk and/or eggs

Biological: Blood collection
Patients less than 5 kg : 2 ml Patients over 5 kg : 3 ml Patients over 10 kg : 5 ml

Outcome Measures

Primary Outcome Measures

  1. Plasma concentration of casein-specific immunoglobulin G4 and egg-specific immunoglobulin G4 [Day 0]

Secondary Outcome Measures

  1. Plasma concentration of casein-specific immunoglobulin E and egg-specific immunoglobulin E [Day 0]

  2. Total immunoglobulin E plasma concentration [Day 0]

  3. Plasma concentration of casein-specific immunoglobulin G4 / plasma concentration of casein-specific immunoglobulin E ratio [Day 0]

  4. Plasma concentration of egg-specific immunoglobulin G4 / plasma concentration of egg-specific immunoglobulin E ratio [Day 0]

  5. Plasma concentration of casein-specific immunoglobulin G4 / total immunoglobulin E plasma concentration ratio [Day 0]

  6. Plasma concentration of egg-specific immunoglobulin G4 / total immunoglobulin E plasma concentration ratio [Day 0]

  7. Plasma metabolomic analysis [Day 0]

Eligibility Criteria

Criteria

Ages Eligible for Study:
1 Month to 18 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Minors aged 0 to 18

  • In consultation or hospitalized for an oral food challenge for milk or eggs

  • To undergo a blood test

Exclusion Criteria:

Minors with immune deficiency, chronic inflammatory disease or immunosuppressive or immunomodulator treatment

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hôpital Necker Enfants malades Paris France 75015

Sponsors and Collaborators

  • Assistance Publique - Hôpitaux de Paris

Investigators

  • Principal Investigator: Guillaume Lezmi, MD, PhD, Assistance Publique - Hôpitaux de Paris

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier:
NCT03776474
Other Study ID Numbers:
  • APHP180057
  • 2018-A01972-53
First Posted:
Dec 14, 2018
Last Update Posted:
Jan 13, 2021
Last Verified:
Jan 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Assistance Publique - Hôpitaux de Paris
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 13, 2021